TCRX
NASDAQTScan Therapeutics Inc.
Website
News25/Ratings9
News · 26 weeks29-20%
2025-10-262026-04-19
Mix1190d
- SEC Filings6(55%)
- Other5(45%)
Latest news
25 items- SECSEC Form DEF 14A filed by TScan Therapeutics Inc.DEF 14A - TScan Therapeutics, Inc. (0001783328) (Filer)
- PRTScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceWALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 3:00 p.m. Eastern Time. A webcast of the fireside chat will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of the webcast will be available on the Company's website for 90 days following the event. About TSca
- SECSEC Form PRE 14A filed by TScan Therapeutics Inc.PRE 14A - TScan Therapeutics, Inc. (0001783328) (Filer)
- SECSEC Form 8-K filed by TScan Therapeutics Inc.8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- PRCombination Therapies Reshape Oncology: A $748B Market Shifts Standard of CareIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 19, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035[1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032[2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ
- SECSEC Form S-8 filed by TScan Therapeutics Inc.S-8 - TScan Therapeutics, Inc. (0001783328) (Filer)
- SECSEC Form 10-K filed by TScan Therapeutics Inc.10-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- SECTScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- PRTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatePresented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Announced expansion of heme program with FDA clearance of TSC-102-A01 and TSC-102-A03 targeting CD45, in patients with HLA types A*01:01 and A*03:01 Cash and cash equivalents continue to fund operations into the second half of 2027 WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (
- PRTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 targeting CD45, for patients with HLA types A*01:01 and A*03:01 Plans to initiate Phase 1 study of both TSC-102 candidates in the second half of 2026 WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced completion of enrollment into Cohort C of the ALLOHA™ study. Patients in Coh
- PRTScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceWALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a hybrid presentation followed by an analyst-led Q&A session at the TD Cowen 46th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA on Wednesday, March 4, 2026 at 11:50 a.m. Eastern Time. A webcast of the presentation will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of t
- INSIDERSEC Form 4 filed by Chief Financial Officer Amello Jason4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Macbeath Gavin4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- INSIDERSEC Form 4 filed by Officer Dworak Leiden4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Louis Chrystal4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- INSIDERSEC Form 4 filed by Officer Zdraveski Zoran4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- SECTScan Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- INSIDERLarge owner Lynx1 Capital Management Lp bought $73,552 worth of shares (81,732 units at $0.90) and bought $71,974 worth of shares (80,069 units at $0.90) (SEC Form 4)4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- PRSmart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma PipelinesIssued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning single-asset risk for companies engineering multiple drugs from validated mechanisms[1]. Antibody-drug conjugate pipelines expanding past 200 clinical candidates demonstrate how platform technologies enable rapid target-swapping while preserving core therapeutic advantages, creating sustainable competitive moats that command premium valuations[2]. This structural shift toward modularity positions companies with proprietary engines to capture multiple therapeutic opportunit
- PRBlood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection PointsIssued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f
- PRTScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market OpportunitiesWALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated data from the ALLOHA™ Phase 1 trial being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition and the future market opportunity for its heme program. The virtual event will take place on Monday, December 8, at 8:00 a.m. ET. The event will provide an in-depth review of the poster presented at the ASH A
- SECSEC Form 8-K filed by TScan Therapeutics Inc.8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- ANALYSTTScan Therapeutics downgraded by Morgan StanleyMorgan Stanley downgraded TScan Therapeutics from Overweight to Equal-Weight
- SECSEC Form 10-Q filed by TScan Therapeutics Inc.10-Q - TScan Therapeutics, Inc. (0001783328) (Filer)
- SECTScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TScan Therapeutics, Inc. (0001783328) (Filer)